Literature DB >> 16730699

Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat.

Dineshree V Naiker1, Stanley V Catts, Vibeke S Catts, Kuldip S Bedi, Lesley J Bryan-Lluka.   

Abstract

The purpose of the present study was to determine antipsychotic doses that achieve 80% striatal dopamine D2-receptor occupancy for haloperidol, risperidone and olanzapine in rats. Wistar rats were treated with normal saline vehicle (controls), haloperidol (0.25 and 0.5 mg/kg/day), risperidone (3, 5 and 6 mg/kg/day) and olanzapine (5 and 10 mg/kg/day) for 7 days via osmotic minipumps. Striatal and cerebellar tissue were collected and in vivo dopamine D2-receptor occupancies were determined using 3H-raclopride. The doses required to achieve dopamine D2-receptor occupancy of 80% in 11- and 24-week old rats were: haloperidol 0.25 mg/kg/day, risperidone 5 mg/kg/day and olanzapine 10 mg/kg/day.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730699     DOI: 10.1016/j.ejphar.2006.04.048

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

2.  Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits.

Authors:  Ann N Hoffman; Jeffrey P Cheng; Ross D Zafonte; Anthony E Kline
Journal:  Life Sci       Date:  2008-08-31       Impact factor: 5.037

3.  In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia.

Authors:  Laura C Amann; Michael J Gandal; Robert Lin; Yuling Liang; Steven J Siegel
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

4.  Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia.

Authors:  Eleanor H Simpson; Christoph Kellendonk; Ryan D Ward; Vanessa Richards; Olga Lipatova; Stephen Fairhurst; Eric R Kandel; Peter D Balsam
Journal:  Biol Psychiatry       Date:  2011-03-16       Impact factor: 13.382

5.  Aripiprazole Increases the PKA Signalling and Expression of the GABAA Receptor and CREB1 in the Nucleus Accumbens of Rats.

Authors:  Bo Pan; Jiamei Lian; Xu-Feng Huang; Chao Deng
Journal:  J Mol Neurosci       Date:  2016-02-19       Impact factor: 3.444

6.  The impact of motivation on cognitive performance in an animal model of the negative and cognitive symptoms of schizophrenia.

Authors:  Ryan D Ward; Vanessa Winiger; Kerin K Higa; Julia B Kahn; Eric R Kandel; Peter D Balsam; Eleanor H Simpson
Journal:  Behav Neurosci       Date:  2015-04-27       Impact factor: 1.912

7.  Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.

Authors:  David O'Sullivan; Laura Green; Sarrabeth Stone; Pirooz Zareie; Marie Kharkrang; Dahna Fong; Bronwen Connor; Anne Camille La Flamme
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

8.  Novel research translates to clinical cases of schizophrenic and cocaine psychosis.

Authors:  João V Nunes; Patricia A Broderick
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

9.  The Effects of Antipsychotics on the Synaptic Plasticity Gene Homer1a Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted.

Authors:  Felice Iasevoli; Elisabetta Filomena Buonaguro; Camilla Avagliano; Annarita Barone; Anna Eramo; Licia Vellucci; Andrea de Bartolomeis
Journal:  Int J Mol Sci       Date:  2020-08-03       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.